Synopsis

The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
Response Date	Jul 10, 2026 12:00:00 AM EDT
Posting Date	Jun 08, 2026 12:00:00 AM EDT
Archive Date	Aug 30, 2026 12:00:00 AM EDT
Award Ceiling	2,900,000
Award Floor	N/a
Cost Sharing	No

Eligibility

Eligible Applicants	Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility", State governments
Additional Info on Eligibility:	"Domestic" means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.

Additional Information

Agency Name	Health Resources and Services Administration
Link to Additional Information:	N/a
Grantor Contact Information:	If you have difficulty accessing the full announcement electronically, please contact: GrantSolutions Help Desk Phone: 301-443-7432

CFDA Program(s)

• 93.110: Special Projects of Regional and National Significance